PH24090A - 17beta-(cyclopropylamino)androst-5-en-3beta-ol and related compounds useful as c17020 lyase inhibitors - Google Patents

17beta-(cyclopropylamino)androst-5-en-3beta-ol and related compounds useful as c17020 lyase inhibitors

Info

Publication number
PH24090A
PH24090A PH36817A PH36817A PH24090A PH 24090 A PH24090 A PH 24090A PH 36817 A PH36817 A PH 36817A PH 36817 A PH36817 A PH 36817A PH 24090 A PH24090 A PH 24090A
Authority
PH
Philippines
Prior art keywords
androst
cyclopropylamino
17beta
3beta
related compounds
Prior art date
Application number
PH36817A
Other languages
English (en)
Inventor
Michael R Angelastro
Thomas R Blohm
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of PH24090A publication Critical patent/PH24090A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Detergent Compositions (AREA)
PH36817A 1987-04-22 1988-04-19 17beta-(cyclopropylamino)androst-5-en-3beta-ol and related compounds useful as c17020 lyase inhibitors PH24090A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4117287A 1987-04-22 1987-04-22

Publications (1)

Publication Number Publication Date
PH24090A true PH24090A (en) 1990-03-05

Family

ID=21915133

Family Applications (1)

Application Number Title Priority Date Filing Date
PH36817A PH24090A (en) 1987-04-22 1988-04-19 17beta-(cyclopropylamino)androst-5-en-3beta-ol and related compounds useful as c17020 lyase inhibitors

Country Status (19)

Country Link
EP (1) EP0288053B1 (xx)
JP (1) JP2711672B2 (xx)
KR (1) KR960015037B1 (xx)
CN (1) CN88102176A (xx)
AT (1) ATE67211T1 (xx)
AU (1) AU606677B2 (xx)
CA (1) CA1326234C (xx)
DE (1) DE3864725D1 (xx)
DK (1) DK217588A (xx)
ES (1) ES2038712T3 (xx)
FI (1) FI88397C (xx)
GR (1) GR3002713T3 (xx)
HU (1) HU198511B (xx)
IL (1) IL86139A (xx)
NO (1) NO169346C (xx)
NZ (1) NZ224288A (xx)
PH (1) PH24090A (xx)
PT (1) PT87294B (xx)
ZA (1) ZA882717B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891367A (en) * 1987-04-22 1990-01-02 Merrell Dow Pharmaceuticals Inc. 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US4954488A (en) * 1989-06-14 1990-09-04 Merrell Dow Pharmaceuticals Inc. Method of treating hyperaldosteronism using 17β-cyclopropylaminoandrostene derivatives
US4966898A (en) * 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US5256408A (en) * 1990-06-12 1993-10-26 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5252319A (en) * 1990-06-12 1993-10-12 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5209926A (en) * 1990-06-12 1993-05-11 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
DK0633893T3 (da) * 1992-03-31 2000-04-17 Btg Int Ltd 17-Substituerede steroider, der er nyttige ved cancerbehandling
US5486511A (en) * 1993-05-25 1996-01-23 Merrell Dow Pharmaceuticals Inc. 4-amino-17β-(cyclopropyloxy)androst-4-en-3-one, 4-amino-17β-(cyclopropylamino)androst-4-en-3-one and related compounds as C17-20 lyase and 5α-reductase
CN100572363C (zh) 2000-11-17 2009-12-23 武田药品工业株式会社 咪唑衍生物、其制备方法及其用途
ATE502030T1 (de) 2000-11-20 2011-04-15 Takeda Pharmaceutical Imidazolderivate, verfahren zu deren herstellung und deren verwendung
DE60139639D1 (de) 2000-12-08 2009-10-01 Takeda Pharmaceutical Substituierte thiazolderivate mit 3-pyridylgruppen, verfahren zu deren herstellung und deren verwendung
UA105794C2 (uk) 2009-06-26 2014-06-25 Новартіс Аг 1,3-ДИЗАМІЩЕНІ ПОХІДНІ ІМІДАЗОЛІДИН-2-ОНУ ЯК ІНГІБІТОРИ Cyp17
US9132105B2 (en) 2010-08-04 2015-09-15 Pellficure Pharmaceuticals, Inc. Treatment of prostate carcinoma
US8946260B2 (en) 2010-09-16 2015-02-03 Novartis Ag 17α-hydroxylase/C17,20-lyase inhibitors
ES2656218T3 (es) 2011-04-28 2018-02-26 Novartis Ag Inhibidores de 17 alfa-hidroxilasa/C17,20-liasa
CA2902335C (en) 2013-03-14 2021-09-14 Pellficure Pharmaceuticals, Inc. Novel therapy for prostate carcinoma
US10093620B2 (en) 2014-09-12 2018-10-09 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
EP3528799A1 (en) 2016-10-24 2019-08-28 Pellficure Pharmaceuticals, Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL302932A (xx) * 1962-12-31
US4891367A (en) * 1987-04-22 1990-01-02 Merrell Dow Pharmaceuticals Inc. 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors

Also Published As

Publication number Publication date
NO169346C (no) 1992-06-10
JPS63284195A (ja) 1988-11-21
GR3002713T3 (en) 1993-01-25
IL86139A0 (en) 1988-11-15
CA1326234C (en) 1994-01-18
NO169346B (no) 1992-03-02
ZA882717B (en) 1988-10-17
PT87294A (pt) 1988-05-01
KR880012633A (ko) 1988-11-28
JP2711672B2 (ja) 1998-02-10
KR960015037B1 (ko) 1996-10-24
HUT47307A (en) 1989-02-28
AU606677B2 (en) 1991-02-14
EP0288053B1 (en) 1991-09-11
FI88397B (fi) 1993-01-29
AU1471988A (en) 1988-10-27
HU198511B (en) 1989-10-30
CN88102176A (zh) 1988-11-23
PT87294B (pt) 1992-08-31
DK217588A (da) 1988-10-23
DK217588D0 (da) 1988-04-21
FI881877A (fi) 1988-10-23
NZ224288A (en) 1989-12-21
DE3864725D1 (de) 1991-10-17
FI881877A0 (fi) 1988-04-21
ATE67211T1 (de) 1991-09-15
NO881746L (no) 1988-10-24
EP0288053A1 (en) 1988-10-26
IL86139A (en) 1993-02-21
NO881746D0 (no) 1988-04-21
FI88397C (fi) 1993-05-10
ES2038712T3 (es) 1993-08-01

Similar Documents

Publication Publication Date Title
PH24090A (en) 17beta-(cyclopropylamino)androst-5-en-3beta-ol and related compounds useful as c17020 lyase inhibitors
ZA906308B (en) 4-substituted 17beta-(cyclopropylamino)androst-5-en-3beta-ol and related compounds useful as c17-20lyase inhibitors
GB9514451D0 (en) Sustained-release formulation
GR3020797T3 (en) 4-substituted 17-beta-(cyclopropyloxy)androst-5-EN-3-beta-OL and related compounds useful as C17-20 lyase inhibitors
NZ224287A (en) 17b-(cyclopropyloxy)androst-5-en-3b-ol and related compounds useful as c 17-20 lyase inhibitors for treating androgen-dependent disorders
EP0305181A3 (en) Ethyl-(+)-apovincaminate for treating demyelinization clinical patterns of autoimmune origin
GR3020492T3 (en) New process for the preparation of nojirimycin and related compounds
GR3022779T3 (en) Compounds and methods for treatment of thromboembolic disorders